"""
Question: 1101 

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. For the 28 selected PLLV patients a total of 590 VL measurements were performed during routine patient monitoring between initiation of ART and study closure. PR-RT amplification and sequencing was successful for 154 of the 378 samples.

Rationale: The study describes original patient selection, measurements, and sequencing results from a specific hospital cohort, indicating that it reports newly generated clinical and sequencing data rather than summarizing previously published datasets.

Answer: Yes
"""

"""
Question: 1102 

Evidence: PR-RT amplification and sequencing was successful for 154 of the 378 samples. Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software.

Rationale: The methods and results explicitly state that HIV genomic regions (PR-RT) were amplified and sequenced, confirming that the paper reports HIV sequences.

Answer: Yes
"""

"""
Question: 1103 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014).

Rationale: The study analyzes clinical plasma samples from patients rather than viruses passaged in cell culture; there is no description of serial in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database. Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software.

Rationale: The paper conducts genotypic resistance testing and interpretation without describing any phenotypic antiretroviral susceptibility assays.

Answer: No
"""

"""
Question: 2101 

Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software. A maximum likelihood phylogenetic tree was constructed of all collected sequences.

Rationale: Although sequences were generated and analyzed, the text does not provide any GenBank accession numbers for these sequences.

Answer: No
"""

"""
Question: 2102 

Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software. A maximum likelihood phylogenetic tree was constructed of all collected sequences.

Rationale: The paper does not list any GenBank accession numbers for clinical isolates (or any isolates), so none are reported for non-laboratory isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA) and sequences were analysed using SmartGene (IDNS™) software. A maximum likelihood phylogenetic tree was constructed of all collected sequences.

Rationale: The paper does not include any GenBank accession numbers; therefore, none can be listed.

Answer: NA
"""

"""
Question: 2202 

Evidence: Historical DRMs, detected before study initiation, were observed in three patients. Patient 13 was infected with an NRTI-resistant strain (mutations D67N, T69D and T215C) and this variant was consistently found in the five samples genotyped during PLLV. New DRM, not present at study initiation or in earlier samples, were found in four isolated samples from four different patients: K101E in patient 1, Y188C in patient 13, I50L in patient 19 and K219E in patient 21.

Rationale: The paper specifies mutations detected for individual patients, effectively providing per-isolate (per-patient, per-sample) mutation lists.

Answer: Yes
"""

"""
Question: 2301 

Evidence: Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART. Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital.

Rationale: The title and methods clearly state the infection is with HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years). All except one were infected with a subtype B HIV-1.

Rationale: The results section directly reports the subtypes, indicating predominantly subtype B with one non-B infection.

Answer: Subtype B (all except one patient; one non-B subtype)
"""

"""
Question: 2303 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.

Rationale: PR-RT refers to the protease (PR) and reverse transcriptase (RT) regions of pol; these were the sequenced genes.

Answer: Protease (PR) and Reverse Transcriptase (RT) regions of pol
"""

"""
Question: 2304 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.

Rationale: PR-RT are part of the HIV pol gene; thus, the study reports results from pol sequences.

Answer: Yes
"""

"""
Question: 2401 

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital.

Rationale: Ghent University Hospital is in Belgium; therefore, sequences are from Belgium.

Answer: Belgium (Ghent)
"""

"""
Question: 2402 

Evidence: An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014). Follow-up started 6 months after antiretroviral therapy (ART) initiation and ended at virological failure or study closure (February 2014).

Rationale: The paper specifies that retrospective sequencing covered up to January 2013 with additional sampling through February 2014; exact earlier start years are not provided.

Answer: Through January 2013 (retrospective) and up to February 2014 (follow-up)
"""

"""
Question: 2502 

Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA). Mixtures in sequences were identified if the secondary peak height was at least 20% of the dominant peak height at that position.

Rationale: The ABI3130 is a capillary Sanger sequencer, indicating Sanger sequencing was used.

Answer: Yes
"""

"""
Question: 2503 

Evidence: Sequencing was performed on the ABI3130 Sequencer (Applied Biosystems, Foster City, CA, USA). An ultrasensitive version of this protocol was used to sequence PR-RT ... and a three-step PCR was used instead of the two-step nested PCR.

Rationale: The methods describe Sanger sequencing workflows and do not mention any next-generation sequencing technology.

Answer: No
"""

"""
Question: 2504 

Evidence: Briefly, 20 µl of RNA extract was subjected to 60 min of reverse transcription at 45°C and 10 cycles of amplification ... Finally, a third PCR reaction of 40 cycles was performed using 2 µl of the second PCR product. Sequencing was performed on the ABI3130 Sequencer.

Rationale: The protocol involves RT-PCR amplification from plasma RNA followed by direct sequencing; there is no mention of molecular cloning of amplicons prior to sequencing.

Answer: No
"""

"""
Question: 2505 

Evidence: Finally, a third PCR reaction of 40 cycles was performed using 2 µl of the second PCR product. Sequencing was performed on the ABI3130 Sequencer.

Rationale: The study used bulk PCR amplification rather than single-genome amplification; no single-genome sequencing was performed.

Answer: No
"""

"""
Question: 2506 

Evidence: Briefly, 20 µl of RNA extract was subjected to ... amplification ... Finally, a third PCR reaction of 40 cycles was performed ... Sequencing was performed on the ABI3130 Sequencer.

Rationale: The methods do not include molecular cloning; they directly sequenced PCR products.

Answer: No
"""

"""
Question: 2601 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.

Rationale: The study explicitly sequenced HIV from plasma samples.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.

Rationale: Only plasma samples are mentioned; there is no mention of PBMC-derived sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: PR-RT amplification and sequencing was successful for 154 of the 378 samples. A sufficient amount of residual plasma for resistance analysis was available for 378 samples.

Rationale: The successful sequencing count reported for plasma samples is 154.

Answer: 154
"""

"""
Question: 2604 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively.

Rationale: The study did not report PBMC sequencing; therefore, the number of PBMC samples sequenced is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: LLV was defined as a VL between 20 and 250 copies/ml. PLLV was defined as LLV in at least half of all VL measurements from 6 months after ART initiation until patient selection for the study (January 2013).

Rationale: Individuals had persistent low-level viremia (detectable viral loads), indicating ongoing viraemia rather than complete suppression.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Briefly, 20 µl of RNA extract was subjected to ... reverse transcription ... An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples. 

Rationale: Sequencing was performed from plasma viral RNA; there is no indication of sequencing from proviral DNA reservoirs.

Answer: No
"""

"""
Question: 2701 

Evidence: These 23 patients were all male with a median age of 48 years (IQR 43–54 years). 

Rationale: The reported ages indicate adult participants, and there is no mention of infants or children.

Answer: No
"""

"""
Question: 2702 

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. All patients provided written informed consent.

Rationale: The paper describes an observational hospital cohort with ethics approval; it does not state whether any participants were in clinical trials.

Answer: NA
"""

"""
Question: 2703 

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. All patients provided written informed consent.

Rationale: There is no indication that all individuals were enrolled in a clinical trial; trial participation is not described.

Answer: NA
"""

"""
Question: 3101 

Evidence: For the 28 selected PLLV patients a total of 590 VL measurements were performed during routine patient monitoring between initiation of ART and study closure. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014).

Rationale: The study applied the sequencing protocol to samples from the 28 selected patients, indicating these individuals had samples obtained for sequencing.

Answer: 28
"""

"""
Question: 3102 

Evidence: For the 28 selected PLLV patients ... A sufficient amount of residual plasma for resistance analysis was available for 378 samples ... PR-RT amplification and sequencing was successful for 154 of the 378 samples. To assess drug resistance during long-term follow-up, only patients with at least three genotyped longitudinal samples were included in further analysis (Table 1). These 23 patients were all male.

Rationale: Although 28 patients were selected and sequencing was attempted, only 23 had at least three genotyped samples; the text does not state whether the remaining five had any successful sequencing at all.

Answer: NA
"""

"""
Question: 4101 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol.

Rationale: This indicates sequencing of pre-ART (ART-naive) samples.

Answer: Yes
"""

"""
Question: 4102 

Evidence: Ten (43.5%) patients were drugexperienced before study inclusion. An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014).

Rationale: The cohort included ART-experienced individuals, and their samples were sequenced longitudinally.

Answer: Yes
"""

"""
Question: 4103 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. Ten (43.5%) patients were drugexperienced before study inclusion.

Rationale: The study includes sequencing from both pre-ART (naive) samples and from ART-experienced individuals.

Answer: Yes
"""

"""
Question: 4104 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. 

Rationale: The paper does not provide a count of how many pre-ART samples were successfully sequenced; it only states that pre-ART samples were assessed.

Answer: NA
"""

"""
Question: 4105 

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice. Table 1 lists an Initial ART regimen and a Final ART regimen for each patient.

Rationale: The paper provides initial and final regimens and summary switching frequency but not a complete, detailed ART history for each individual.

Answer: No
"""

"""
Question: 4201 

Evidence: Patients with PLLV were retrospectively selected from the cohort of HIV-1-infected patients followed at the Ghent University Hospital. Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol.

Rationale: Although pre-ART samples were assessed, the paper does not estimate or report the prevalence of transmitted drug resistance in a defined ART-naive population.

Answer: No
"""

"""
Question: 4202 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample using an in-house protocol. Historical DRMs, detected before study initiation, were observed in three patients.

Rationale: The detection of DRMs in pre-ART samples constitutes information on pretreatment drug resistance within this cohort.

Answer: Yes
"""

"""
Question: 4301 

Evidence: Table 1 footnote: ABC, abacavir; ATV, atazanavir; AZT, zidovudine; DRM, drug resistance mutation; DRV, darunavir; EFV, efavirenz; ETV, etravirine; FTC, emtricitabine; LPV, lopinavir; MVC, maraviroc; r, ritonavir-boosted; RAL, raltegravir; TDF, tenofovir disoproxil fumarate; 3TC, lamivudine. Patient 6 Final ART regimen: DRVr+ABC+3TC+RAL.

Rationale: The regimens listed include NRTIs (TDF, FTC, 3TC, ABC, AZT), NNRTIs (EFV, NVP, ETV), PIs (ATV/r, LPV/r, DRV/r), an INSTI (RAL), and a CCR5 antagonist (MVC).

Answer: NRTIs, NNRTIs, Protease inhibitors, Integrase inhibitors, CCR5 antagonist
"""

"""
Question: 4302 

Evidence: Table 1 footnote includes RAL, raltegravir. Patient 20 Final ART regimen: RAL+TDF+FTC.

Rationale: The presence of raltegravir-containing regimens indicates that some individuals received integrase inhibitors.

Answer: Yes
"""

"""
Question: 4303 

Evidence: Table 1 footnote includes LPV, lopinavir; ATV, atazanavir; DRV, darunavir. Patient 13 Final ART regimen: DRVr+TDF+FTC.

Rationale: Multiple regimens include ritonavir-boosted protease inhibitors (LPV/r, ATV/r, DRV/r), indicating PI use.

Answer: Yes
"""

"""
Question: 4304 

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice.

Rationale: The heterogeneity and frequent changes show that individuals did not all receive the same ART.

Answer: No
"""

"""
Question: 4305 

Evidence: Patient 6 Final ART regimen: DRVr+ABC+3TC+RAL. Patient 20 Final ART regimen: RAL+TDF+FTC.

Rationale: Because some individuals received an INSTI (raltegravir), not all were INSTI-naive.

Answer: No
"""

"""
Question: 4403 

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period. 

Rationale: If only 5 of 23 stayed on their initial regimen, then 23−5 = 18 individuals received more than one regimen.

Answer: 18
"""

"""
Question: 4404 

Evidence: Nine patients (39.1%) switched or intensified ART more than twice.

Rationale: The paper reports how many switched more than twice but does not provide enough detail to determine exactly how many received more than two distinct regimens (e.g., those who switched exactly twice would also have >2 regimens but are not quantified).

Answer: NA
"""

"""
Question: 4405 

Evidence: Changes in treatment regimen were frequent, only five patients (21.7%) remained on the initial regimen during the study period and nine patients (39.1%) switched or intensified ART more than twice.

Rationale: The number of regimen changes varied across individuals, indicating they did not all receive the same number of regimens.

Answer: No
"""

"""
Question: 4406 

Evidence: Only five patients (21.7%) remained on the initial regimen during the study period.

Rationale: Since only a minority stayed on a single regimen, not all individuals received only one ART regimen.

Answer: No
"""

"""
Question: 4501 

Evidence: Table 1 footnote lists RAL (raltegravir) and MVC (maraviroc) among others, but dolutegravir is not mentioned anywhere in the regimens. Patient 20 Final ART regimen: RAL+TDF+FTC.

Rationale: The regimens include raltegravir as the INSTI; there is no mention of dolutegravir use.

Answer: 0
"""

"""
Question: 4502 

Evidence: Table 1 footnote includes DRV, darunavir. Multiple Final ART regimens include DRVr (e.g., patients 1, 2, 3, 6, 10, 13, 14, 15, 16, 18, 19, 22, 23).

Rationale: Counting individuals with darunavir-containing regimens in Table 1 yields 13 persons.

Answer: 13
"""

"""
Question: 5101 

Evidence: Historical DRMs, detected before study initiation, were observed in three patients. New DRM, not present at study initiation or in earlier samples, were found in four isolated samples from four different patients: K101E in patient 1, Y188C in patient 13, I50L in patient 19 and K219E in patient 21.

Rationale: Unique individuals with DRMs are patients 12, 13, 14 (historical) and 1, 19, 21 (new); patient 13 appears in both groups, yielding 6 individuals with one or more DRMs.

Answer: 6
"""

"""
Question: 5102 

Evidence: Resistance mutations in PR-RT were assessed. New DRM detected were K101E, Y188C, I50L and K219E.

Rationale: Only protease and reverse transcriptase regions were sequenced and reported; no integrase resistance mutations were examined or found.

Answer: 0
"""

"""
Question: 5103 

Evidence: Historical DRMs included D67N, T69D and T215C. New DRM detected were K101E, Y188C, I50L and K219E.

Rationale: None of the reported mutations are the canonical TDF-associated resistance mutations (e.g., K65R); therefore, no individuals had TDF-resistance mutations.

Answer: 0
"""

"""
Question: 5104 

Evidence: Resistance mutations in PR-RT were assessed. New DRM detected were K101E, Y188C, I50L and K219E.

Rationale: The study did not sequence integrase and reports no INSTI resistance mutations.

Answer: NA
"""

"""
Question: 6101 

Evidence: Sequencing was performed on the ABI3130 Sequencer ... and sequences were analysed using SmartGene ... DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database.

Rationale: The paper reports only genotypic analyses; no phenotypic susceptibility testing methods are described.

Answer: NA
"""

"""
Question: 6102 

Evidence: DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database. Sequencing was performed on the ABI3130 Sequencer.

Rationale: There is no mention of IC50 or IC90 determinations in the text.

Answer: No
"""

"""
Question: 6103 

Evidence: DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database. Sequencing was performed on the ABI3130 Sequencer.

Rationale: The paper contains no phenotypic fold-change data.

Answer: No
"""

"""
Question: 6104 

Evidence: Sequencing was performed on the ABI3130 Sequencer ... DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database.

Rationale: No phenotypic susceptibility assay is described.

Answer: NA
"""

"""
Question: 6105 

Evidence: The modifications for the ultrasensitive protocol consisted of ... PCR ... Sequencing was performed on the ABI3130 Sequencer. 

Rationale: There is no mention of replication capacity measurements in the methods or results.

Answer: No
"""

"""
Question: 6106 

Evidence: Sequencing was performed on the ABI3130 Sequencer ... DRM were defined as mutations with a score >10 according to the Stanford HIV Drug Resistance Database.

Rationale: No phenotypic testing of drugs was performed; therefore, no drugs were tested for phenotypic susceptibility.

Answer: NA
"""

"""
Question: 7101 

Evidence: Resistance mutations in PR-RT were assessed in the last pre-ART plasma sample ... and ... in all plasma samples collected retrospectively ... Sequencing was performed on the ABI3130 Sequencer.

Rationale: The study sequenced viruses directly from patient plasma; there is no description of site-directed mutagenesis constructs.

Answer: No
"""

"""
Question: 7102 

Evidence: An ultrasensitive version of this protocol was used to sequence PR-RT of all plasma samples collected retrospectively between 6 months post-ART initiation and January 2013 and all samples collected until study closure (February 2014). 

Rationale: The paper analyzes clinical samples and does not report any in vitro passage experiments.

Answer: No
"""